This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

2 Mar 2012

Lonza & Eclipse Therapeutics Ink Pact for Novel Therapeutic Antibody

Lonza and Eclipse has announced an agreement for the production of Eclipse's novel cancer therapeutic antibody, ET-101.

Lonza has signed an agreement with private biotechnology company Eclipse Therapeutics for the production of Eclipse’s novel cancer therapeutic antibody, ET-101.


ET-101 is under investigation for the inhibition of the growth of cancer stem cells.


Cancer stem cells are a small subset of cells within a tumour that are thought to play a critical role in tumour initiation, recurrence and metastasis. ET-101 is a novel therapeutic antibody designed to target these cancer stem cells. Eliminating cancer stem cells, in conjunction with other therapies that address the tumour bulk, represents a new cancer treatment that could offer advantages over existing methods and a solution for chemoresistance.



Related News